MedPath

Effect of Low Carbohydrate Versus Low Fat Diet in the Treatment of Dyslipidemia in Obese Children With Metabolic Syndrome

Not Applicable
Completed
Conditions
Metabolic Syndrome
Obesity
Dyslipidemias
Interventions
Other: Standard low fat diet
Other: Carbohydrate restricted group
Registration Number
NCT03937960
Lead Sponsor
University of Alabama at Birmingham
Brief Summary

Two-arm, parallel design with children between the ages of 10 - 18 with obesity and metabolic syndrome randomized (15 per group) to reduced-carbohydrate diet or a reduced-fat diet for 8 weeks.

Detailed Description

Two-arm, parallel design with participants randomized (15 per group) to reduced-carbohydrate diet or a reduced-fat diet for 8 weeks. Anthropometric evaluations, lab work for lipid levels, insulin and C peptide levels, resting energy expenditure evaluation, DXA scan and cardiovascular markers will occur at baseline during the initial clinic visit. Individual dietary counseling will be provided at baseline and as well as weekly diet-specific support will be provided with a phone call from the PI. Dietary intake will be assessed with weekly food records (weeks 1-8). The return visit on week 8 will include a visit identical to the initial visit except the resting energy expenditure will not be revaluated, and the participants will be asked to answer a questionnaire about the diet they were consuming.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria

3 out of 5 of the following criteria

  • Metabolic syndrome with dyslipidemia
  • (HDL <40mg/dL
  • Triglyceride (TG) TG>150mg/dL)
  • Glucose intolerance (fasting blood sugar >100mg/dL)
  • Central adiposity (Waist circumference ≥90th percentile or adult cutoff if lower)
  • Systolic BP ≥130 mm Hg or diastolic BP ≥85 mm Hg or treatment of previously diagnosed hypertension
Read More
Exclusion Criteria
  • Patient on medications known to induce dyslipidemia (systemic steroids, immunosuppressants)
  • Pregnancy
  • Untreated thyroid disease, heart disease, cancer, kidney disease
  • Children on statin/fibrate treatments or other lipid-lowering medications
  • Prior surgical procedure for weight control or current weight loss medication
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Standard/Low fat diet groupStandard low fat dietThe control, low-fat diet will contain 55:25:20 %energy from CHO: protein: fat based on the United States Department of Agriculture (USDA) My Plate Daily Food Plan and our groups previous work. For example, an 1800 kcal/d plan will include 5 ounces lean meats, 3 cups low-fat dairy, 6 ounces of whole grains, 1 ½ cups fruit, 2 ½ cups vegetables (starchy and non-starchy) and limited fats.
Carbohydrate restricted groupCarbohydrate restricted groupThis diet is designed to minimize intake of carbohydrate sources such as added sugars, high glycemic grains, and fructose. It will provide a fixed amount of carbohydrate, and a total calorie goal - with proteins and fats to satiety. During the first two weeks of the intervention, carbohydrate (CHO) sources will be primarily derived from leafy greens and non-starchy vegetables and CHO intake will be equally distributed across meals throughout the day. At week three, additional CHO sources will be added back to the diet prescription including nuts, unsweetened yogurt, and low-glycemic fruits such as apples and berries.
Primary Outcome Measures
NameTimeMethod
Dyslipidemia MeasuresBaseline to 8 weeks

Percentage change in concentration of serum small low-density lipoprotein size

Insulin Resistance IndicesBaseline to 8 weeks

Percentage change in Serum measure of Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)

HOMA_IR is a scale where a higher number means worse outcome

Secondary Outcome Measures
NameTimeMethod
Insulin Resistance IndicesBaseline

Baseline Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)

HOMA_IR is a scale where a higher number means worse outcome

Surrogate Markers of Vascular Endothelial Function as Measured by Augmentation IndexBaseline to 8 weeks

The Augmentation Index a measure of peripheral arterial stiffness

Surrogate Markers of Vascular Endothelial FunctionBaseline to 8 weeks

Percentage Change in Pulse wave velocity

Body CompositionBaseline to 8 weeks

Percent Change in Dual-energy X-ray absorptiometry (DXA) body fat

Trial Locations

Locations (2)

Bhuvana Sunil

🇺🇸

Birmingham, Alabama, United States

University of Alabama at Birmingham

🇺🇸

Birmingham, Alabama, United States

© Copyright 2025. All Rights Reserved by MedPath